We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Treponemal Subspecies Discriminated by LAMP

By LabMedica International staff writers
Posted on 26 Apr 2018
Human yaws is a tropical skin disease of children caused by the bacterium Treponema pallidum subsp. More...
pertenue (TPE). Skin ulcers are the most characteristic clinical manifestations associated with infection in all three active disease stages, primary, secondary, and tertiary yaws.

Although it is possible to distinguish current infection, active or latent, from past infection when non-treponemal and treponemal tests are used in combination, it remains impossible based on serology and in some instances clinical manifestations, to differentiate yaws infection (TPE) from syphilis, caused by subsp. pallidum (TPA) or bejel, caused by the subsp. endemicum (TEN).

A team of scientists working with the Institute for Primate Research (Göttingen, Germany) used loop-mediated isothermal amplification (LAMP) assays to rapidly differentiate infection with any of the three Treponema pallidum subspecies (pallidum (TPA), pertenue (TPE), and endemicum (TEN)) and which are known to infect humans and nonhuman primates (NHPs). Four TPA, six human, and two NHP TPE strains, as well as two human TEN strains were used to establish and validate the LAMP assays.

Three different LAMP assays were designed. First, the team generated a LAMP assay that is able to detect DNA of all three TP subspecies (TPA, TPE, and TEN). Another LAMP assay was designed to distinguish TPE strain infection from infection with TPA or TEN strains. A third LAMP assay that differentiates between infection with TPE or TEN and infection with TPA strains was established. LAMP reactions were performed using the Mast Isoplex DNA Kit. All reactions were run on a MircoAmp Fast Optical 96-well reaction plate.

The scientists reported that all three LAMP assays were highly specific for the target DNA. Amplification was rapid from 5 to 15 minutes, and within a range of 10E+6 to 10E+2 of target DNA molecules. Performance in non-human primate (NHP) clinical samples was similar to the one seen in human TPE strains. The LAMP assay targeting the gene was positive for all tested TP strain samples including the four TPA, six human TPE, two simian TPE, and the two human TEN strains. The LAMP assay that uses a part of the TP_0619 gene generated positive results for all TPE strains including simian TPE strains as well as the two human TEN strains.

The authors concluded that the newly designed LAMP assays provide proof of concept for a diagnostic tool that enhances yaws clinical diagnosis. It is highly specific for the target DNA and does not require expensive laboratory equipment. Test results can potentially be interpreted with the naked eye, which makes it suitable for the use in remote clinical settings. The study was published on April 12, 2018, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Institute for Primate Research


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.